$5.08
8.96% yesterday
Nasdaq, Nov 15, 10:13 pm CET
ISIN
US00650F1093
Symbol
ADPT

Adaptive Biotechnologies Corp Stock price

$5.08
+0.11 2.21% 1M
+1.18 30.26% 6M
+0.18 3.67% YTD
+0.80 18.69% 1Y
-27.50 84.41% 3Y
-23.43 82.18% 5Y
-14.92 74.60% 10Y
Nasdaq, Closing price Fri, Nov 15 2024
-0.50 8.96%
ISIN
US00650F1093
Symbol
ADPT
Sector
Industry

Key metrics

Market capitalization $749.70m
Enterprise Value $730.70m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 4.12
P/S ratio (TTM) P/S ratio 4.23
P/B ratio (TTM) P/B ratio 3.35
Revenue growth (TTM) Revenue growth -1.34%
Revenue (TTM) Revenue $177.28m
EBIT (operating result TTM) EBIT $-166.27m
Free Cash Flow (TTM) Free Cash Flow $-114.54m
Cash position $243.33m
EPS (TTM) EPS $-1.34
P/E forward negative
P/S forward 4.64
EV/Sales forward 4.53
Short interest 7.80%
Show more

Is Adaptive Biotechnologies Corp a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Adaptive Biotechnologies Corp Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Adaptive Biotechnologies Corp forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Adaptive Biotechnologies Corp forecast:

Buy
86%
Hold
14%

Financial data from Adaptive Biotechnologies Corp

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
177 177
1% 1%
100%
- Direct Costs 87 87
8% 8%
49%
90 90
6% 6%
51%
- Selling and Administrative Expenses 139 139
5% 5%
79%
- Research and Development Expense 97 97
7% 7%
55%
-146 -146
12% 12%
-82%
- Depreciation and Amortization 20 20
31% 31%
11%
EBIT (Operating Income) EBIT -166 -166
15% 15%
-94%
Net Profit -195 -195
0% 0%
-110%

In millions USD.

Don't miss a Thing! We will send you all news about Adaptive Biotechnologies Corp directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Adaptive Biotechnologies Corp Stock News

Neutral
Seeking Alpha
8 days ago
Adaptive Biotechnologies Corporation (NASDAQ:ADPT ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Karina Calzadilla - Head of IR Chad Robins - CEO and Co-Founder Kyle Piskel - CFO Susan Bobulsky - Chief Commercial Officer Conference Call Participants Dan Brennan - TD Cowen Mark Massaro - BTIG Matt Sykes - Goldman Sachs Maggie Boeye - William Blair Corey Rosen...
Neutral
GlobeNewsWire
9 days ago
clonoSEQ is the first and only assay to receive Medicare coverage for MRD assessment in MCL Coverage leverages new Medicare episode pricing established based on updated clonoSEQ gapfill rate SEATTLE, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system int...
Neutral
GlobeNewsWire
about one month ago
SEATTLE, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the third quarter 2024 after market close on Thursday, November 7, 2024. Company manage...
More Adaptive Biotechnologies Corp News

Company Profile

Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. It harnesses the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. The company was founded by Chad Robins, Harlan Robins, and Chris Carlson in September 2009 and is headquartered in Seattle, WA.

Head office United States
CEO Chad Robins
Employees 709
Founded 2009
Website www.adaptivebiotech.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today